Ruth Langsford shares devastating health fears 5 months after Eamonn Holmes split

TV host Ruth Langsford has expressed her fear of developing Alzheimer's disease, having witnessed both her parents suffer from the condition. The 64-year-old presenter revealed to Woman and Home that while she doesn't fear ageing itself, she is concerned about the health issues that can accompany it, including Alzheimer's.

She said: "I lost my darling dad, Dennis, to Alzheimer's, and now, sadly, my mum, 93-year-old Joan, has the disease. Every time I forget something, instead of thinking it's a senior moment, I think 'Oh my God. Is this the start of Alzheimer's?' I don't fear getting older. I embrace my age and I never lie about it. I'm 64 and I'm very happy to be 64.

"I only worry about age in respect to my health. I think old age is wonderful, and I see many very active, interesting and brilliant older people and I hope that will be me."

This comes after Ruth and Eamonn Holmes announced their separation after 14 years of marriage. Earlier this year, Ruth humorously hinted at GB News presenter Eamonn when she mentioned she was "throwing a lot of stuff out at the minute".

Among the discarded items was Eamonn's stair lift, which reportedly amused Ruth's friends. A source told the Daily Mail: "Ruth doesn't need it," reports the M anchester Evening News.

"She's super-fit and healthy but she knew Eamonn probably would struggle when he had to go the house to get some bits he needed for the holiday. The bedrooms are upstairs and he needed to get to them. It might seem petty but Ruth's friends think it is absolutely hilarious as they think he has really taken her for a ride."

While Ruth may be in good health, her confession of fearing Alzheimer's comes just days after the NHS announced it wouldn't fund a new drug that can slow the disease's progression. Despite the drug – known as donanemab - being found to stall the deadly condition, its impact was not deemed worth the cost.

NICE's Director of medicines evaluation, Helen Knight, stated: "For NICE to be able to approve a medicine for use in the NHS it must provide additional benefits to patients, and it must also represent a good use of NHS resources and taxpayers' money."

"The cost-effectiveness estimate for donanemab is five to six times above what NICE normally considers an acceptable use of NHS resources."

Alzheimer's Research UK's Chief executive, Hilary Evans-Newton, commented that the announcement marked "another frustrating setback for people affected by Alzheimer's disease".